Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ANNX
stocks logo

ANNX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.347
+5.22%
--
--
-0.407
+9.91%
--
--
-0.423
+24.51%
Estimates Revision
The market is revising No Change the revenue expectations for Annexon, Inc. (ANNX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 106.45%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+106.45%
In Past 3 Month
Wall Street analysts forecast ANNX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANNX is 14.00 USD with a low forecast of 8.00 USD and a high forecast of 27.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast ANNX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANNX is 14.00 USD with a low forecast of 8.00 USD and a high forecast of 27.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.480
sliders
Low
8.00
Averages
14.00
High
27.00
Current: 4.480
sliders
Low
8.00
Averages
14.00
High
27.00
Wells Fargo
NULL
to
Overweight
upgrade
$14 -> $27
2025-11-19
Reason
Wells Fargo
Price Target
$14 -> $27
2025-11-19
upgrade
NULL
to
Overweight
Reason
Wells Fargo raised the firm's price target on Annexon to $27 from $14 and keeps an Overweight rating on the shares. The firm is raising its probability of success to 55% from 10% that vonaprument's Phase 3 trial in GA will be positive in the second half of 2026. Wells believes the setup offers a significant, asymmetric risk/reward skew with the potential for VC-like upside in the next 12 months.
BofA
Buy
downgrade
$9 -> $8
2025-11-16
Reason
BofA
Price Target
$9 -> $8
2025-11-16
downgrade
Buy
Reason
BofA lowered the firm's price target on Annexon to $8 from $9 and keeps a Buy rating on the shares. The firm updated smid-cap biotech models following the Q3 reports.
Wells Fargo
Derek Archila
Overweight
maintain
$14
2025-07-10
Reason
Wells Fargo
Derek Archila
Price Target
$14
2025-07-10
maintain
Overweight
Reason
Wells Fargo analyst Derek Archila spoke to Annexon as the shares traded down earlier today post the circulation of a tweet from a month ago by a physician. A doctor claimed the FDA requested a confirmatory study of tanruprubart in the U.S. as it did not accept the comparison to the International GBS Outcomes Study database as evidence of efficacy in western Guillain-Barre syndrome, the analyst tells investors in a research note. Wells spoke to management, who said the post is not factual. Annexon's CEO noted this post was one week before the company's FDA meeting, Wells points out. The company told the firm that the FDA has not requested another confirmatory trial. After selling off earlier in the day, shares of Annexon are up 2% to $2.82 in afternoon trading. Wells keeps an Overweight rating on the shares with a $14 price target. It recommends buying the shares on weakness.
H.C. Wainwright
Buy
downgrade
$20 -> $14
2025-05-13
Reason
H.C. Wainwright
Price Target
$20 -> $14
2025-05-13
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Annexon to $14 from $20 and keeps a Buy rating on the shares. The firm reduced the stock's multiple and increased its discount rates to better align with current investor sentiment, elevated cost of capital, and reduced appetite for early-stage clinical risk. Annexon announced that it is on track to meet with the FDA for tanruprubart around Q2, the analyst tells investors in a research note.
Needham
Joseph Stringer
Strong Buy
Reiterates
$16
2025-03-04
Reason
Needham
Joseph Stringer
Price Target
$16
2025-03-04
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Andrew Fein
Strong Buy
Reiterates
$30
2024-12-17
Reason
HC Wainwright & Co.
Andrew Fein
Price Target
$30
2024-12-17
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Annexon Inc (ANNX.O) is -3.45, compared to its 5-year average forward P/E of -3.70. For a more detailed relative valuation and DCF analysis to assess Annexon Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.70
Current PE
-3.45
Overvalued PE
-1.23
Undervalued PE
-6.16

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.36
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.50
Undervalued EV/EBITDA
-3.23

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.05
Current PS
0.00
Overvalued PS
1.90
Undervalued PS
-1.79
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ANNX News & Events

Events Timeline

(ET)
2025-12-01
16:20:00
Clear Street Initiates Buy Rating on Annexon with $17 Price Target
select
2025-11-17 (ET)
2025-11-17
09:29:08
BofA Reduces Annexon Price Target from $9 to $8
select
2025-11-12 (ET)
2025-11-12
23:21:49
Annexon Prices 25.1M Share Spot Secondary Offering at $2.60
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
11-21Yahoo Finance
Annexon Stock Soars Following Director's $5.06 Million Share Acquisition
  • Stock Performance: Annexon (ANNX) stock experienced an 8.6% increase in trading on Thursday.
  • Director Purchase: The rise in stock price followed the purchase of $5.06 million worth of shares by director Muneer Satter.
[object Object]
Preview
5.0
11-20NASDAQ.COM
Insider Buying Update for Thursday, November 20: ANNX, TH

  • Annexon Insider Purchase: Muneer A. Satter of Annexon made a significant purchase of 1.5 million shares of ANNX at $3.37 each, totaling $5.06 million, and saw a 50.4% gain during trading, with shares reaching $5.07.

  • Target Hospitality Insider Purchase: Stephen Robertson bought 145,000 shares of Target Hospitality at $6.85 each for a total of $993,250, and is currently up 4.8% based on a trading high of $7.18.

[object Object]
Preview
4.0
11-20Benzinga
Wells Fargo Keeps Overweight Rating on Annexon and Increases Price Target to $27

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.

  • Market Winning Tools: Benzinga Pro is designed to help traders win in the markets every day with accurate stock market intelligence.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Annexon Inc (ANNX) stock price today?

The current price of ANNX is 4.48 USD — it has decreased -0.22 % in the last trading day.

arrow icon

What is Annexon Inc (ANNX)'s business?

Annexon, Inc. is a clinical-stage biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. It identifies and characterizes the role of the classical complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology, using its proprietary platform. Its lead candidate, ANX005, an investigational, full-length monoclonal antibody (mAb), is formulated for intravenous administration as the potential first targeted treatment for patients with Guillain-Barre Syndrome (GBS). It is advancing ANX1502, a novel small-molecule inhibitor of classical complement designed for oral administration in a range of chronic autoimmune diseases. It is also advancing ANX007, designed to block C1q locally in the eye, to provide complete protection against excess classical complement activity and the loss of photoreceptor neurons.

arrow icon

What is the price predicton of ANNX Stock?

Wall Street analysts forecast ANNX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANNX is 14.00 USD with a low forecast of 8.00 USD and a high forecast of 27.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Annexon Inc (ANNX)'s revenue for the last quarter?

Annexon Inc revenue for the last quarter amounts to -57.02M USD, increased 44.56 % YoY.

arrow icon

What is Annexon Inc (ANNX)'s earnings per share (EPS) for the last quarter?

Annexon Inc. EPS for the last quarter amounts to -52352000.00 USD, increased 63.48 % YoY.

arrow icon

What changes have occurred in the market's expectations for Annexon Inc (ANNX)'s fundamentals?

The market is revising No Change the revenue expectations for Annexon, Inc. (ANNX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 106.45%.
arrow icon

How many employees does Annexon Inc (ANNX). have?

Annexon Inc (ANNX) has 100 emplpoyees as of December 05 2025.

arrow icon

What is Annexon Inc (ANNX) market cap?

Today ANNX has the market capitalization of 668.52M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free